<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39339469</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1420-3049</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>18</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>20</Day></PubDate></JournalIssue><Title>Molecules (Basel, Switzerland)</Title><ISOAbbreviation>Molecules</ISOAbbreviation></Journal><ArticleTitle>Some Aspects and Convergence of Human and Veterinary Drug Repositioning.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">4475</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/molecules29184475</ELocationID><Abstract><AbstractText>Drug innovation traditionally follows a de novo approach with new molecules through a complex preclinical and clinical pathway. In addition to this strategy, drug repositioning has also become an important complementary approach, which can be shorter, cheaper, and less risky. This review provides an overview of drug innovation in both human and veterinary medicine, with a focus on drug repositioning. The evolution of drug repositioning and the effectiveness of this approach are presented, including the growing role of data science and computational modeling methods in identifying drugs with potential for repositioning. Certain business aspects of drug innovation, especially the relevant factors of market exclusivity, are also discussed. Despite the promising potential of drug repositioning for innovation, it remains underutilized, especially in veterinary applications. To change this landscape for mutual benefits of human and veterinary drug innovation, further exploitation of the potency of drug repositioning is necessary through closer cooperation between all stakeholders, academia, industry, pharmaceutical authorities, and innovation policy makers, and the integration of human and veterinary repositioning into a unified innovation space. For this purpose, the establishment of the conceptually new "One Health Drug Repositioning Platform" is proposed. Oncology is one of the disease areas where this platform can significantly support the development of new drugs for human and dog (or other companion animals) anticancer therapies. As an example of the utilization of human and veterinary drugs for veterinary repositioning, the use of COX inhibitors to treat dog cancers is reviewed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mag</LastName><ForeName>Patrik</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, University of Veterinary Medicine, István Street 2, 1078 Budapest, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Laboratory of Infectious Animal Diseases, Antimicrobial Resistance, Veterinary Public Health and Food Chain Safety, University of Veterinary Medicine, István Street 2, 1078 Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nemes-Terényi</LastName><ForeName>Melinda</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, University of Veterinary Medicine, István Street 2, 1078 Budapest, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Laboratory of Infectious Animal Diseases, Antimicrobial Resistance, Veterinary Public Health and Food Chain Safety, University of Veterinary Medicine, István Street 2, 1078 Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jerzsele</LastName><ForeName>Ákos</ForeName><Initials>Á</Initials><Identifier Source="ORCID">0000-0002-3380-0827</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, University of Veterinary Medicine, István Street 2, 1078 Budapest, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Laboratory of Infectious Animal Diseases, Antimicrobial Resistance, Veterinary Public Health and Food Chain Safety, University of Veterinary Medicine, István Street 2, 1078 Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mátyus</LastName><ForeName>Péter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>National Laboratory of Infectious Animal Diseases, Antimicrobial Resistance, Veterinary Public Health and Food Chain Safety, University of Veterinary Medicine, István Street 2, 1078 Budapest, Hungary.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RRF-2.3.1-21-2022-00001</GrantID><Agency>National Recovery Fund</Agency><Country /></Grant><Grant><GrantID>2020-1.1.2-PIACI-KFI-2021-00246</GrantID><Agency>Development of an Antibacterial Resistance Inhibitor in Veterinary Medicine, Development of a Supporting Repository Platform</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Molecules</MedlineTA><NlmUniqueID>100964009</NlmUniqueID><ISSNLinking>1420-3049</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019155">Veterinary Drugs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D058492" MajorTopicYN="Y">Drug Repositioning</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019155" MajorTopicYN="Y">Veterinary Drugs</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">drug repositioning</Keyword><Keyword MajorTopicYN="N">human and veterinary drug innovation</Keyword><Keyword MajorTopicYN="N">one health drug repositioning</Keyword><Keyword MajorTopicYN="N">repositioning of COX inhibitors</Keyword></KeywordList><CoiStatement>This study was sponsored by the National Research, Development and Innovation Office (Hungary) and the E-GROUP ICT SOFTWARE Information Technology Private Limited Company. There is no conflicts of interest between the authors and the sponsors.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39339469</ArticleId><ArticleId IdType="pmc">PMC11433938</ArticleId><ArticleId IdType="doi">10.3390/molecules29184475</ArticleId><ArticleId IdType="pii">molecules29184475</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>DiMasi J.A., Grabowski H.G., Hansen R.W. Innovation in the Pharmaceutical Industry: New Estimates of R&amp;D Costs. J. Health Econ. 2016;47:20–33. doi: 10.1016/j.jhealeco.2016.01.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhealeco.2016.01.012</ArticleId><ArticleId IdType="pubmed">26928437</ArticleId></ArticleIdList></Reference><Reference><Citation>Measuring the Return of Pharmaceutical Innovation 2019.  [(accessed on 24 July 2024)].  Available online:  https://www.statista.com/study/69635/pharmaceutical-randd-return-of-innovation-report-2019/</Citation></Reference><Reference><Citation>Prasad V., Mailankody S. Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues after Approval. JAMA Intern. Med. 2017;177:1569–1575. doi: 10.1001/jamainternmed.2017.3601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2017.3601</ArticleId><ArticleId IdType="pmc">PMC5710275</ArticleId><ArticleId IdType="pubmed">28892524</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinkson I.V., Madej B., Stahlberg E.A. Accelerating Therapeutics for Opportunities in Medicine: A Paradigm Shift in Drug Discovery. Front. Pharmacol. 2020;11:770. doi: 10.3389/fphar.2020.00770.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.00770</ArticleId><ArticleId IdType="pmc">PMC7339658</ArticleId><ArticleId IdType="pubmed">32694991</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Life Sciences Outlook.  [(accessed on 24 July 2024)].  Available online:  https://www2.deloitte.com/us/en/pages/life-sciences-and-health-care/articles/gx-new-global-life-sciences-sector-outlook.html.</Citation></Reference><Reference><Citation>CDER Drug Approvals U.S. 2008–2023.  [(accessed on 24 July 2024)].  Available online:  https://www.statista.com/statistics/817534/annual-novel-drug-approvals-by-cder/</Citation></Reference><Reference><Citation>Measuring the Return from Pharmaceutical Innovation 2019.  [(accessed on 24 July 2024)].  Available online:  https://www2.deloitte.com/ch/en/pages/life-sciences-and-healthcare/articles/measuring-the-return-from-pharmaceutical-innovation-2019.html.</Citation></Reference><Reference><Citation>Fernald K.D.S., Förster P.C., Claassen E., van de Burgwal L.H. The Pharmaceutical Productivity Gap—Incremental Decline in R&amp;D Efficiency despite Transient Improvements. Drug Discov. Today. 2024;29:104160. doi: 10.1016/j.drudis.2024.104160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2024.104160</ArticleId><ArticleId IdType="pubmed">39241979</ArticleId></ArticleIdList></Reference><Reference><Citation>Animal Health and Veterinary Drugs.  [(accessed on 24 July 2024)].  Available online:  https://lasttechnology.it/en/animal-health-and-veterinary-drugs-the-current-landscape/</Citation></Reference><Reference><Citation>Hunter R.P., Shryock T.R., Cox B.R., Butler R.M., Hammelman J.E. Overview of the Animal Health Drug Development and Registration Process: An Industry Perspective. Future Med. Chem. 2011;3:881–886. doi: 10.4155/fmc.11.55.</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/fmc.11.55</ArticleId><ArticleId IdType="pubmed">21644833</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhodes L. Terminology Matters: Understanding the Differences in Animal vs. Human Drug Development.  [(accessed on 24 July 2024.)].  Available online:  https://kisacoresearch.com/sites/default/files/documents/ahinnovationusa_linda_rhodes.pdf.</Citation></Reference><Reference><Citation>Center for Veterinary Medicine  From an Idea to the Marketplace: The Journey of an Animal Drug through the Approval Process. FDA 2022.  [(accessed on 24 July 2024.)]; Available online:  https://www.fda.gov/animal-veterinary/animal-health-literacy/idea-marketplace-journey-animal-drug-through-approval-process.</Citation></Reference><Reference><Citation>Center for Veterinary Medicine  FDA Regulation of Animal Drugs. FDA 2023.  [(accessed on 24 July 2024.)]; Available online:  https://www.fda.gov/animal-veterinary/resources-you/fda-regulation-animal-drugs.</Citation></Reference><Reference><Citation>Veterinary Medicinal Products Regulation|European Medicines Agency.  [(accessed on 24 July 2024)].  Available online:  https://www.ema.europa.eu/en/veterinary-regulatory-overview/veterinary-medicinal-products-regulation.</Citation></Reference><Reference><Citation>Center for Veterinary Medicine  Recent Animal Drug Approvals. FDA 2024.  [(accessed on 24 July 2024)]; Available online:  https://www.fda.gov/animal-veterinary/approved-animal-drug-products-green-book/recent-animal-drug-approvals.</Citation></Reference><Reference><Citation>Why Are There So Few Treatments Approved for Animals?—Anivive Lifesciences.  [(accessed on 24 July 2024)].  Available online:  https://www.anivive.com/learn/article/why-are-there-so-few-drug-approved-specifically-for-veterinary-use.</Citation></Reference><Reference><Citation>Why Animal Health Is the Next Big Growth Area.  [(accessed on 24 July 2024)].  Available online:  https://www.lifescienceleader.com/doc/why-animal-health-is-the-next-big-growth-area-0001.</Citation></Reference><Reference><Citation>Expedited Programs for Serious Conditions—Drugs and Biologics.  [(accessed on 11 September 2024)]; Available online:  https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expedited-programs-serious-conditions-drugs-and-biologics.</Citation></Reference><Reference><Citation>PRIME: Priority Medicines|European Medicines Agency.  [(accessed on 24 July 2024)].  Available online:  https://www.ema.europa.eu/en/human-regulatory-overview/research-development/prime-priority-medicines.</Citation></Reference><Reference><Citation>Pharmaceutical Legislation.  [(accessed on 24 July 2024)].  Available online:  https://www.efpia.eu/pharmaceutical-legislation/</Citation></Reference><Reference><Citation>Langedijk J., Mantel-Teeuwisse A.K., Slijkerman D.S., Schutjens M.-H.D.B. Drug Repositioning and Repurposing: Terminology and Definitions in Literature. Drug Discov. Today. 2015;20:1027–1034. doi: 10.1016/j.drudis.2015.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2015.05.001</ArticleId><ArticleId IdType="pubmed">25975957</ArticleId></ArticleIdList></Reference><Reference><Citation>Pantziarka P., Bouche G., André N. “Hard” Drug Repurposing for Precision Oncology: The Missing Link? Front. Pharmacol. 2018;9:637. doi: 10.3389/fphar.2018.00637.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2018.00637</ArticleId><ArticleId IdType="pmc">PMC6010551</ArticleId><ArticleId IdType="pubmed">29962954</ArticleId></ArticleIdList></Reference><Reference><Citation>Raju T.N. The Nobel Chronicles. Lancet. 2000;355:1022. doi: 10.1016/S0140-6736(05)74775-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(05)74775-9</ArticleId><ArticleId IdType="pubmed">10768469</ArticleId></ArticleIdList></Reference><Reference><Citation>Wermuth C.G. Selective Optimization of Side Activities: The SOSA Approach. Drug Discov. Today. 2006;11:160–164. doi: 10.1016/S1359-6446(05)03686-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1359-6446(05)03686-X</ArticleId><ArticleId IdType="pubmed">16533714</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburn T.T., Thor K.B. Drug Repositioning: Identifying and Developing New Uses for Existing Drugs. Nat. Rev. Drug Discov. 2004;3:673–683. doi: 10.1038/nrd1468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd1468</ArticleId><ArticleId IdType="pubmed">15286734</ArticleId></ArticleIdList></Reference><Reference><Citation>Khambhati K., Alessa A.H., Singh V. An Overview to Drug Repurposing. Prog. Mol. Biol. Transl. Sci. 2024;205:1–8. doi: 10.1016/bs.pmbts.2024.03.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.pmbts.2024.03.026</ArticleId><ArticleId IdType="pubmed">38789176</ArticleId></ArticleIdList></Reference><Reference><Citation>Team D.D.W. Therapeutic Drug Repurposing, Repositioning and Rescue Part I: Overview.  [(accessed on 24 July 2024)].  Available online:  https://www.ddw-online.com/therapeutic-drug-repurposing-repositioning-and-rescue-part-i-overview-1463-201412/</Citation></Reference><Reference><Citation>Polamreddy P., Gattu N. The Drug Repurposing Landscape from 2012 to 2017: Evolution, Challenges, and Possible Solutions. Drug Discov. Today. 2019;24:789–795. doi: 10.1016/j.drudis.2018.11.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2018.11.022</ArticleId><ArticleId IdType="pubmed">30513339</ArticleId></ArticleIdList></Reference><Reference><Citation>Latif K., Ullah A., Shkodina A.D., Boiko D.I., Rafique Z., Alghamdi B.S., Alfaleh M.A., Ashraf G.M. Drug Reprofiling History and Potential Therapies against Parkinson’s Disease. Front. Pharmacol. 2022;13:1028356. doi: 10.3389/fphar.2022.1028356.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.1028356</ArticleId><ArticleId IdType="pmc">PMC9643740</ArticleId><ArticleId IdType="pubmed">36386233</ArticleId></ArticleIdList></Reference><Reference><Citation>Pantziarka P., Pirmohamed M., Mirza N. New Uses for Old Drugs. BMJ. 2018;361:k2701. doi: 10.1136/bmj.k2701.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.k2701</ArticleId><ArticleId IdType="pubmed">29945952</ArticleId></ArticleIdList></Reference><Reference><Citation>Weth F.R., Hoggarth G.B., Weth A.F., Paterson E., White M.P.J., Tan S.T., Peng L., Gray C. Unlocking Hidden Potential: Advancements, Approaches, and Obstacles in Repurposing Drugs for Cancer Therapy. Br. J. Cancer. 2024;130:703–715. doi: 10.1038/s41416-023-02502-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41416-023-02502-9</ArticleId><ArticleId IdType="pmc">PMC10912636</ArticleId><ArticleId IdType="pubmed">38012383</ArticleId></ArticleIdList></Reference><Reference><Citation>Jourdan J.-P., Bureau R., Rochais C., Dallemagne P. Drug Repositioning: A Brief Overview. J. Pharm. Pharmacol. 2020;72:1145–1151. doi: 10.1111/jphp.13273.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jphp.13273</ArticleId><ArticleId IdType="pmc">PMC7262062</ArticleId><ArticleId IdType="pubmed">32301512</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Repurposing: Approaches, Methods and Considerations|Elsevier.  [(accessed on 24 July 2024)].  Available online:  https://www.elsevier.com/industry/drug-repurposing.</Citation></Reference><Reference><Citation>Trivedi J., Mohan M., Byrareddy S.N. Drug Repurposing Approaches to Combating Viral Infections. J. Clin. Med. 2020;9:3777. doi: 10.3390/jcm9113777.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9113777</ArticleId><ArticleId IdType="pmc">PMC7700377</ArticleId><ArticleId IdType="pubmed">33238464</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudrapal M., Khairnar S.J., Jadhav A.G., Rudrapal M., Khairnar S.J., Jadhav A.G. Drug Repurposing—Hypothesis, Molecular Aspects and Therapeutic Applications. IntechOpen; Rijeka, Croatia: 2020. Drug Repurposing (DR): An Emerging Approach in Drug Discovery.</Citation></Reference><Reference><Citation>Roessler H.I., Knoers N.V.A.M., van Haelst M.M., van Haaften G. Drug Repurposing for Rare Diseases. Trends Pharmacol. Sci. 2021;42:255–267. doi: 10.1016/j.tips.2021.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2021.01.003</ArticleId><ArticleId IdType="pubmed">33563480</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua Y., Dai X., Xu Y., Xing G., Liu H., Lu T., Chen Y., Zhang Y. Drug Repositioning: Progress and Challenges in Drug Discovery for Various Diseases. Eur. J. Med. Chem. 2022;234:114239. doi: 10.1016/j.ejmech.2022.114239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2022.114239</ArticleId><ArticleId IdType="pmc">PMC8883737</ArticleId><ArticleId IdType="pubmed">35290843</ArticleId></ArticleIdList></Reference><Reference><Citation>Pushpakom S., Iorio F., Eyers P.A., Escott K.J., Hopper S., Wells A., Doig A., Guilliams T., Latimer J., McNamee C., et al. Drug Repurposing: Progress, Challenges and Recommendations. Nat. Rev. Drug Discov. 2019;18:41–58. doi: 10.1038/nrd.2018.168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2018.168</ArticleId><ArticleId IdType="pubmed">30310233</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan S., Agnihotri J., Patil S., Khan N. Drug Repurposing: A Futuristic Approach in Drug Discovery. J. Pharm. Biol. Sci. 2023;11:66–69. doi: 10.18231/j.jpbs.2023.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.18231/j.jpbs.2023.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra A.S., Vasanthan M., Malliappan S.P. Drug Repurposing: A Leading Strategy for New Threats and Targets. ACS Pharmacol. Transl. Sci. 2024;7:915–932. doi: 10.1021/acsptsci.3c00361.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsptsci.3c00361</ArticleId><ArticleId IdType="pmc">PMC11019736</ArticleId><ArticleId IdType="pubmed">38633585</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller S., Moos W., Munk B., Munk S. Drug Discovery. Woodhead Publishing; Sawston, UK: 2017. pp. 183–279.</Citation></Reference><Reference><Citation>The Latest on Drug Failure and Approval Rates.  [(accessed on 26 July 2024)].  Available online:  https://www.science.org/content/blog-post/latest-drug-failure-and-approval-rates.</Citation></Reference><Reference><Citation>Würth R., Thellung S., Bajetto A., Mazzanti M., Florio T., Barbieri F. Drug-Repositioning Opportunities for Cancer Therapy: Novel Molecular Targets for Known Compounds. Drug Discov. Today. 2016;21:190–199. doi: 10.1016/j.drudis.2015.09.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2015.09.017</ArticleId><ArticleId IdType="pubmed">26456577</ArticleId></ArticleIdList></Reference><Reference><Citation>Begley C.G., Ashton M., Baell J., Bettess M., Brown M.P., Carter B., Charman W.N., Davis C., Fisher S., Frazer I., et al. Drug Repurposing: Misconceptions, Challenges, and Opportunities for Academic Researchers. Sci. Transl. Med. 2021;13:eabd5524. doi: 10.1126/scitranslmed.abd5524.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abd5524</ArticleId><ArticleId IdType="pubmed">34550729</ArticleId></ArticleIdList></Reference><Reference><Citation>Panda S., Kumari L., Badwaik H.R., Shanmugarajan D. Chapter 12—Computational Approaches for Drug Repositioning and Repurposing to Combat SARS-CoV-2 Infection. In: Parihar A., Khan R., Kumar A., Kaushik A.K., Gohel H., editors. Computational Approaches for Novel Therapeutic and Diagnostic Designing to Mitigate SARS-CoV-2 Infection. Academic Press; Cambridge, MA, USA: 2022. pp. 247–265.</Citation></Reference><Reference><Citation>Bolognesi M.L. Polypharmacology in a Single Drug: Multitarget Drugs. Curr. Med. Chem. 2013;20:1639–1645. doi: 10.2174/0929867311320130004.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867311320130004</ArticleId><ArticleId IdType="pubmed">23410164</ArticleId></ArticleIdList></Reference><Reference><Citation>Mei Y., Yang B. Rational Application of Drug Promiscuity in Medicinal Chemistry. Future Med. Chem. 2018;10:1835–1851. doi: 10.4155/fmc-2018-0018.</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/fmc-2018-0018</ArticleId><ArticleId IdType="pubmed">30019924</ArticleId></ArticleIdList></Reference><Reference><Citation>Wermuth C.G. Multitargeted Drugs: The End of the “One-Target-One-Disease” Philosophy? Drug Discov. Today. 2004;9:826–827. doi: 10.1016/S1359-6446(04)03213-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1359-6446(04)03213-1</ArticleId><ArticleId IdType="pubmed">15381132</ArticleId></ArticleIdList></Reference><Reference><Citation>Morphy R., Kay C., Rankovic Z. From Magic Bullets to Designed Multiple Ligands. Drug Discov. Today. 2004;9:641–651. doi: 10.1016/S1359-6446(04)03163-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1359-6446(04)03163-0</ArticleId><ArticleId IdType="pubmed">15279847</ArticleId></ArticleIdList></Reference><Reference><Citation>Mátyus P., Rettegi T., Varró A., Papp J.G. New Antiarrhythmic Agents: A Conceptually Novel Approach. Med. Res. Rev. 2000;20:294–303. doi: 10.1002/1098-1128(200007)20:4&lt;294::AID-MED2&gt;3.0.CO;2-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1098-1128(200007)20:4&lt;294::AID-MED2&gt;3.0.CO;2-5</ArticleId><ArticleId IdType="pubmed">10861728</ArticleId></ArticleIdList></Reference><Reference><Citation>Mátyus P., Varga I., Rettegi T., Simay A., Kállay N., Károlyházy L., Kocsis A., Varró A., Pénzes I., Papp J.G. Novel Antiarrhythmic Compounds with Combined Class IB and Class III Mode of Action. Curr. Med. Chem. 2004;11:61–69. doi: 10.2174/0929867043456232.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867043456232</ArticleId><ArticleId IdType="pubmed">14754426</ArticleId></ArticleIdList></Reference><Reference><Citation>Mátyus P., Chai C.L.L. Metabolism-Activated Multitargeting (MAMUT): An Innovative Multitargeting Approach to Drug Design and Development. ChemMedChem. 2016;11:1197–1198. doi: 10.1002/cmdc.201500406.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cmdc.201500406</ArticleId><ArticleId IdType="pubmed">26497424</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsay R.R., Popovic-Nikolic M.R., Nikolic K., Uliassi E., Bolognesi M.L. A Perspective on Multi-Target Drug Discovery and Design for Complex Diseases. Clin. Transl. Med. 2018;7:3. doi: 10.1186/s40169-017-0181-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40169-017-0181-2</ArticleId><ArticleId IdType="pmc">PMC5770353</ArticleId><ArticleId IdType="pubmed">29340951</ArticleId></ArticleIdList></Reference><Reference><Citation>Drent M., Bast A., Bootsma H., Deneer V. Repositioning “old” Drugs to Treat Rare Diseases: Arguing from the Mechanism of Action. Sarcoidosis Vasc. Diffus. Lung Dis. Off. J. WASOG/World Assoc. Sarcoidosis Other Granulomatous Disord. 2016;33:191–194.</Citation><ArticleIdList><ArticleId IdType="pubmed">27537726</ArticleId></ArticleIdList></Reference><Reference><Citation>Low Z.Y., Farouk I.A., Lal S.K. Drug Repositioning: New Approaches and Future Prospects for Life-Debilitating Diseases and the COVID-19 Pandemic Outbreak. Viruses. 2020;12:1058. doi: 10.3390/v12091058.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12091058</ArticleId><ArticleId IdType="pmc">PMC7551028</ArticleId><ArticleId IdType="pubmed">32972027</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R.-S., Loscalzo J. Repurposing Drugs for the Treatment of COVID-19 and Its Cardiovascular Manifestations. Circ. Res. 2023;132:1374–1386. doi: 10.1161/CIRCRESAHA.122.321879.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.122.321879</ArticleId><ArticleId IdType="pmc">PMC10171294</ArticleId><ArticleId IdType="pubmed">37167362</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S., Kumar S. Chapter 6—Molecular Docking: A Structure-Based Approach for Drug Repurposing. In: Roy K., editor. In Silico Drug Design. Academic Press; Cambridge, MA, USA: 2019. pp. 161–189.</Citation></Reference><Reference><Citation>Sadeghi S.S., Keyvanpour M.R. Computational Drug Repurposing: Classification of the Research Opportunities and Challenges. Curr. Comput. Aided Drug Des. 2020;16:354–364. doi: 10.2174/1573409915666190613113822.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1573409915666190613113822</ArticleId><ArticleId IdType="pubmed">31198115</ArticleId></ArticleIdList></Reference><Reference><Citation>Parmar G., Chudasama J.M., Shah A., Patel A. In Silico Pharmacology and Drug Repurposing Approaches. In: Rudrapal M., Khan J., editors. CADD and Informatics in Drug Discovery. Springer Nature; Singapore: 2023. pp. 253–281.</Citation></Reference><Reference><Citation>Gan J., Liu J., Liu Y., Chen S., Dai W., Xiao Z.-X., Cao Y. DrugRep: An Automatic Virtual Screening Server for Drug Repurposing. Acta Pharmacol. Sin. 2023;44:888–896. doi: 10.1038/s41401-022-00996-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41401-022-00996-2</ArticleId><ArticleId IdType="pmc">PMC9549438</ArticleId><ArticleId IdType="pubmed">36216900</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammadi E., Dashti S., Shafizade N., Jin H., Zhang C., Lam S., Tahmoorespur M., Mardinoglu A., Sekhavati M.H. Drug Repositioning for Immunotherapy in Breast Cancer Using Single-Cell Analysis. NPJ Syst. Biol. Appl. 2024;10:37. doi: 10.1038/s41540-024-00359-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41540-024-00359-z</ArticleId><ArticleId IdType="pmc">PMC11001976</ArticleId><ArticleId IdType="pubmed">38589404</ArticleId></ArticleIdList></Reference><Reference><Citation>Pujol A., Mosca R., Farrés J., Aloy P. Unveiling the Role of Network and Systems Biology in Drug Discovery. Trends Pharmacol. Sci. 2010;31:115–123. doi: 10.1016/j.tips.2009.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2009.11.006</ArticleId><ArticleId IdType="pubmed">20117850</ArticleId></ArticleIdList></Reference><Reference><Citation>Arany A., Bolgar B., Balogh B., Antal P., Matyus P. Multi-Aspect Candidates for Repositioning: Data Fusion Methods Using Heterogeneous Information Sources. Curr. Med. Chem. 2013;20:95–107. doi: 10.2174/0929867311302010010.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867311302010010</ArticleId><ArticleId IdType="pubmed">23210850</ArticleId></ArticleIdList></Reference><Reference><Citation>Masoudi-Sobhanzadeh Y., Omidi Y., Amanlou M., Masoudi-Nejad A. Drug Databases and Their Contributions to Drug Repurposing. Genomics. 2020;112:1087–1095. doi: 10.1016/j.ygeno.2019.06.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygeno.2019.06.021</ArticleId><ArticleId IdType="pubmed">31226485</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsson P., De Rosa M.C., Righino B., Olsson M., Florea B.I., Forssell-Aronsson E., Kovács A., Karlsson P., Helou K., Parris T.Z. Integrated Transcriptomics- and Structure-Based Drug Repositioning Identifies Drugs with Proteasome Inhibitor Properties. Sci. Rep. 2024;14:18772. doi: 10.1038/s41598-024-69465-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-69465-6</ArticleId><ArticleId IdType="pmc">PMC11322189</ArticleId><ArticleId IdType="pubmed">39138277</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorman A.W., Reigle J., Chutipongtanate S., Yang J., Shamsaei B., Pilarczyk M., Fazel-Najafabadi M., Adamczak R., Kouril M., Bhatnagar S., et al. Accelerating Drug Discovery and Repurposing by Combining Transcriptional Signature Connectivity with Docking. Sci. Adv. 2024;10:eadj3010. doi: 10.1126/sciadv.adj3010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.adj3010</ArticleId><ArticleId IdType="pmc">PMC11364105</ArticleId><ArticleId IdType="pubmed">39213358</ArticleId></ArticleIdList></Reference><Reference><Citation>Gönen M. Predicting Drug-Target Interactions from Chemical and Genomic Kernels Using Bayesian Matrix Factorization. Bioinformatics. 2012;28:2304–2310. doi: 10.1093/bioinformatics/bts360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bts360</ArticleId><ArticleId IdType="pubmed">22730431</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolgár B., Arany Á., Temesi G., Balogh B., Antal P., Mátyus P. Drug Repositioning for Treatment of Movement Disorders: From Serendipity to Rational Discovery Strategies. Curr. Top. Med. Chem. 2013;13:2337–2363. doi: 10.2174/15680266113136660164.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/15680266113136660164</ArticleId><ArticleId IdType="pubmed">24059461</ArticleId></ArticleIdList></Reference><Reference><Citation>Boudin M., Diallo G., Drancé M., Mougin F. The OREGANO Knowledge Graph for Computational Drug Repurposing. Sci. Data. 2023;10:871. doi: 10.1038/s41597-023-02757-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41597-023-02757-0</ArticleId><ArticleId IdType="pmc">PMC10700660</ArticleId><ArticleId IdType="pubmed">38057380</ArticleId></ArticleIdList></Reference><Reference><Citation>Lotfi Shahreza M., Ghadiri N., Mousavi S.R., Varshosaz J., Green J.R. A Review of Network-Based Approaches to Drug Repositioning. Brief. Bioinform. 2018;19:878–892. doi: 10.1093/bib/bbx017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bib/bbx017</ArticleId><ArticleId IdType="pubmed">28334136</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Zheng S., Chen B., Butte A.J., Swamidass S.J., Lu Z. A Survey of Current Trends in Computational Drug Repositioning. Brief. Bioinform. 2016;17:2–12. doi: 10.1093/bib/bbv020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bib/bbv020</ArticleId><ArticleId IdType="pmc">PMC4719067</ArticleId><ArticleId IdType="pubmed">25832646</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekins S., Puhl A.C., Zorn K.M., Lane T.R., Russo D.P., Klein J.J., Hickey A.J., Clark A.M. Exploiting Machine Learning for End-to-End Drug Discovery and Development. Nat. Mater. 2019;18:435–441. doi: 10.1038/s41563-019-0338-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41563-019-0338-z</ArticleId><ArticleId IdType="pmc">PMC6594828</ArticleId><ArticleId IdType="pubmed">31000803</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad S., Qazi S., Raza K. Chapter 10—Translational Bioinformatics Methods for Drug Discovery and Drug Repurposing. In: Raza K., Dey N., editors. Translational Bioinformatics in Healthcare and Medicine. Volume 13. Academic Press; Cambridge, MA, USA: 2021. pp. 127–139. Advances in Ubiquitous Sensing Applications for Healthcare.</Citation></Reference><Reference><Citation>Park J.-H., Cho Y.-R. Computational Drug Repositioning with Attention Walking. Sci. Rep. 2024;14:10072. doi: 10.1038/s41598-024-60756-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-60756-6</ArticleId><ArticleId IdType="pmc">PMC11066070</ArticleId><ArticleId IdType="pubmed">38698208</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng P., Zhang B., Liu A., Meng Y., Tang X., Yang J., Xu J. Drug Repositioning Based on Tripartite Cross-Network Embedding and Graph Convolutional Network. Expert Syst. Appl. 2024;252:124152. doi: 10.1016/j.eswa.2024.124152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eswa.2024.124152</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X., Jia X., Lu Z., Tang J., Li M. Drug Repositioning with Adaptive Graph Convolutional Networks. Bioinformatics. 2024;40:btad748. doi: 10.1093/bioinformatics/btad748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btad748</ArticleId><ArticleId IdType="pmc">PMC10761094</ArticleId><ArticleId IdType="pubmed">38070161</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y., Dong D., Zhang W., Wang R., Lin Y.-C.-D., Zuo H., Huang H.-Y., Huang H.-D. DrugRepoBank: A Comprehensive Database and Discovery Platform for Accelerating Drug Repositioning. Database. 2024;2024:baae051. doi: 10.1093/database/baae051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/database/baae051</ArticleId><ArticleId IdType="pmc">PMC11240114</ArticleId><ArticleId IdType="pubmed">38994794</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun W., Sanderson P.E., Zheng W. Drug Combination Therapy Increases Successful Drug Repositioning. Drug Discov. Today. 2016;21:1189–1195. doi: 10.1016/j.drudis.2016.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2016.05.015</ArticleId><ArticleId IdType="pmc">PMC4907866</ArticleId><ArticleId IdType="pubmed">27240777</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadegh S., Skelton J., Anastasi E., Bernett J., Blumenthal D.B., Galindez G., Salgado-Albarrán M., Lazareva O., Flanagan K., Cockell S., et al. Network Medicine for Disease Module Identification and Drug Repurposing with the NeDRex Platform. Nat. Commun. 2021;12:6848. doi: 10.1038/s41467-021-27138-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-27138-2</ArticleId><ArticleId IdType="pmc">PMC8617287</ArticleId><ArticleId IdType="pubmed">34824199</ArticleId></ArticleIdList></Reference><Reference><Citation>Bang D., Lim S., Lee S., Kim S. Biomedical Knowledge Graph Learning for Drug Repurposing by Extending Guilt-by-Association to Multiple Layers. Nat. Commun. 2023;14:3570. doi: 10.1038/s41467-023-39301-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-39301-y</ArticleId><ArticleId IdType="pmc">PMC10272215</ArticleId><ArticleId IdType="pubmed">37322032</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L.-C., Soysal E., Zheng W., Zhao Z., Xu H., Sun J. A Weighted and Integrated Drug-Target Interactome: Drug Repurposing for Schizophrenia as a Use Case. BMC Syst. Biol. 2015;9((Suppl. 4)):S2. doi: 10.1186/1752-0509-9-S4-S2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1752-0509-9-S4-S2</ArticleId><ArticleId IdType="pmc">PMC4474536</ArticleId><ArticleId IdType="pubmed">26100720</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu M., Li W., Yu Y., Zhao Y., Xiao L., Lauschke V.M., Cheng Y., Zhang X., Wang Y. Deep Learning Large-Scale Drug Discovery and Repurposing. Nat. Comput. Sci. 2024;4:600–614. doi: 10.1038/s43588-024-00679-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43588-024-00679-4</ArticleId><ArticleId IdType="pubmed">39169261</ArticleId></ArticleIdList></Reference><Reference><Citation>Oprea T.I., Overington J.P. Computational and Practical Aspects of Drug Repositioning. Assay Drug Dev. Technol. 2015;13:299–306. doi: 10.1089/adt.2015.29011.tiodrrr.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/adt.2015.29011.tiodrrr</ArticleId><ArticleId IdType="pmc">PMC4533090</ArticleId><ArticleId IdType="pubmed">26241209</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan G.S.Q., Sloan E.K., Lambert P., Kirkpatrick C.M.J., Ilomäki J. Drug Repurposing Using Real-World Data. Drug Discov. Today. 2023;28:103422. doi: 10.1016/j.drudis.2022.103422.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2022.103422</ArticleId><ArticleId IdType="pubmed">36341896</ArticleId></ArticleIdList></Reference><Reference><Citation>Center for Drug Evaluation and Research. Center for Biologics Evaluation and Research. Oncology Center of Excellence  Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drug and Biological Products.  [(accessed on 26 July 2024)]; Available online:  https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-real-world-data-and-real-world-evidence-support-regulatory-decision-making-drug.</Citation></Reference><Reference><Citation>Wu Y., Warner J.L., Wang L., Jiang M., Xu J., Chen Q., Nian H., Dai Q., Du X., Yang P., et al. Discovery of Noncancer Drug Effects on Survival in Electronic Health Records of Patients with Cancer: A New Paradigm for Drug Repurposing. JCO Clin. Cancer Inform. 2019;3:1–9. doi: 10.1200/CCI.19.00001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/CCI.19.00001</ArticleId><ArticleId IdType="pmc">PMC6693869</ArticleId><ArticleId IdType="pubmed">31141421</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal M., Mehta T.A., Das A., Das A., Shruthi N.R., Pathak S. Repurposing of Drug: Utility of Animal Models. In: Pathak S., Banerjee A., Bisgin A., editors. Handbook of Animal Models and Its Uses in Cancer Research. Springer Nature; Singapore: 2023. pp. 155–173.</Citation></Reference><Reference><Citation>Marshall L.J., Bailey J., Cassotta M., Herrmann K., Pistollato F. Poor Translatability of Biomedical Research Using Animals—A Narrative Review. Altern. Lab. Anim. 2023;51:102–135. doi: 10.1177/02611929231157756.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/02611929231157756</ArticleId><ArticleId IdType="pubmed">36883244</ArticleId></ArticleIdList></Reference><Reference><Citation>Shridhar D., Hittalamani V., Sunilchandra . Repositioning and Repurposing Therapeutic Drugs. Lambert Academic Publishing; London, UK: 2023.</Citation></Reference><Reference><Citation>Hittalamani V.M., Sunilchandra U., Shridhar N.B., Kavitha Rani B., Niranjan D., Mohan B.R. Drug Repurposing with Reference to Veterinary Therapeutics. Pharma Innov. 2022;11:36–45.</Citation></Reference><Reference><Citation>Roeber F., Webster M. Protecting Dogs and Cats against the Australian Paralysis Tick, Ixodes holocyclus (Acari: Ixodidae): A Review of the Australian Acaricide Registration Process. Curr. Res. Parasitol. Vector-Borne Dis. 2021;1:100054. doi: 10.1016/j.crpvbd.2021.100054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.crpvbd.2021.100054</ArticleId><ArticleId IdType="pmc">PMC8906080</ArticleId><ArticleId IdType="pubmed">35284866</ArticleId></ArticleIdList></Reference><Reference><Citation>Sultana T., Jan U., Lee J.I. Double Repositioning: Veterinary Antiparasitic to Human Anticancer. Int. J. Mol. Sci. 2022;23:4315. doi: 10.3390/ijms23084315.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23084315</ArticleId><ArticleId IdType="pmc">PMC9029030</ArticleId><ArticleId IdType="pubmed">35457127</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaiser M., Mäser P., Tadoori L.P., Ioset J.-R., Brun R. Antiprotozoal Activity Profiling of Approved Drugs: A Starting Point toward Drug Repositioning. PLoS ONE. 2015;10:e0135556. doi: 10.1371/journal.pone.0135556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0135556</ArticleId><ArticleId IdType="pmc">PMC4535766</ArticleId><ArticleId IdType="pubmed">26270335</ArticleId></ArticleIdList></Reference><Reference><Citation>Saez-Ayala M., Hoffer L., Abel S., Ben Yaala K., Sicard B., Andrieu G.P., Latiri M., Davison E.K., Ciufolini M.A., Brémond P., et al. From a Drug Repositioning to a Structure-Based Drug Design Approach to Tackle Acute Lymphoblastic Leukemia. Nat. Commun. 2023;14:3079. doi: 10.1038/s41467-023-38668-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-38668-2</ArticleId><ArticleId IdType="pmc">PMC10227015</ArticleId><ArticleId IdType="pubmed">37248212</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T., Guo F., Zhu X., He X., Xie L. Thalidomide and Its Analogues: A Review of the Potential for Immunomodulation of Fibrosis Diseases and Opthalmopathy (Review) Exp. Ther. Med. 2017;14:5251–5257. doi: 10.3892/etm.2017.5209.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2017.5209</ArticleId><ArticleId IdType="pmc">PMC5740745</ArticleId><ArticleId IdType="pubmed">29285050</ArticleId></ArticleIdList></Reference><Reference><Citation>Raedler L.A. Pomalyst (Pomalidomide) Received a New Indication for Patients with Relapsed and/or Refractory Multiple Myeloma. Am. Health Drug Benefits. 2016;9:111–114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5013859</ArticleId><ArticleId IdType="pubmed">27668057</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks N. What Are Regulatory Data and Market Exclusivity? Drug Approval in Europe.  [(accessed on 26 July 2024)].  Available online:  https://somerville-partners.com/what-are-regulatory-data-and-market-exclusivity-drug-approval-in-europe/</Citation></Reference><Reference><Citation>Naylor S., Kauppi M., Schonfeld J.M. Therapeutic Drug Repurposing, Repositioning and Rescue: Part II: Business Review. Drug Discov. World. 2015;16:57–72.</Citation></Reference><Reference><Citation>Oronsky B., Caroen S., Brinkhaus F., Reid T., Stirn M., Kumar R. Patent and Marketing Exclusivities 101 for Drug Developers. Recent. Pat. Biotechnol. 2023;17:257–270. doi: 10.2174/1872208317666230111105223.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1872208317666230111105223</ArticleId><ArticleId IdType="pmc">PMC10242760</ArticleId><ArticleId IdType="pubmed">36635930</ArticleId></ArticleIdList></Reference><Reference><Citation>Exclusivity and Exclusive Marketing Rights Boilerplate for Use in the Following Documents: Memorandum Recommending Approval, Letter to Applicant, and FOI Summary.  [(accessed on 26 July 2024)]; Available online:  https://www.fda.gov/search?s=EXCLUSIVITY+AND+EXCLUSIVE+MARKETING+RIGHTS+BOILERPLATE+FOR+USE+IN+THE+FOLLOWING+DOCUMENTS%3A+MEMORANDUM+RECOMMENDING+APPROVAL%2C+LETTER+TO+APPLICANT%2C+AND+FREEDOM+OF+INFORMATION+SUMMARY+</Citation></Reference><Reference><Citation>Collier R. Drug Patents: The Evergreening Problem. CMAJ. 2013;185:E385–E386. doi: 10.1503/cmaj.109-4466.</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.109-4466</ArticleId><ArticleId IdType="pmc">PMC3680578</ArticleId><ArticleId IdType="pubmed">23630239</ArticleId></ArticleIdList></Reference><Reference><Citation>Bansal Y., Kaur M., Bansal G. Antimicrobial Potential of Benzimidazole Derived Molecules. Mini Rev. Med. Chem. 2019;19:624–646. doi: 10.2174/1389557517666171101104024.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389557517666171101104024</ArticleId><ArticleId IdType="pubmed">29090668</ArticleId></ArticleIdList></Reference><Reference><Citation>First Medical Use. Second or Further Medical Indications.  [(accessed on 26 July 2024)].  Available online:  https://www.dehns.com/first-medical-use-second-or-further-medical-indications/</Citation></Reference><Reference><Citation>Protecting Second Medical Use Inventions in Europe.  [(accessed on 26 July 2024)].  Available online:  https://www.iam-media.com/guide/global-life-sciences/2022/article/protecting-second-medical-use-inventions-in-europe.</Citation></Reference><Reference><Citation>1 First or Further Medical Use of Known Products.  [(accessed on 26 July 2024)].  Available online:  https://www.epo.org/en/legal/guidelines-epc/2024/g_vi_6_1.html.</Citation></Reference><Reference><Citation>Excluded Subject Matter (7)—1st and 2nd Medical Uses|Simmons &amp; Simmons.  [(accessed on 26 July 2024)].  Available online:  https://www.simmons-simmons.com/en/publications/cklhwpzy9181609317t4kt933/excluded-subject-matter-7-1st-and-2-medical-use,%20february%2023,%202021.</Citation></Reference><Reference><Citation>Adachi K. The Patentability of Second and Subsequent Medical Uses in Asia’s Patent Legislation. Asian J. Law Econ. 2023;14:59–75. doi: 10.1515/ajle-2022-0091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/ajle-2022-0091</ArticleId></ArticleIdList></Reference><Reference><Citation>Breckenridge A., Jacob R. Overcoming the Legal and Regulatory Barriers to Drug Repurposing. Nat. Rev. Drug Discov. 2019;18:1–2. doi: 10.1038/nrd.2018.92.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2018.92</ArticleId><ArticleId IdType="pubmed">29880920</ArticleId></ArticleIdList></Reference><Reference><Citation>Aboy M., Liddell K., Liddicoat J., Crespo C., Jordan M. Mapping the European Patent Landscape for Medical Uses of Known Products. Nat. Biotechnol. 2021;39:1336–1343. doi: 10.1038/s41587-021-01104-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-021-01104-1</ArticleId><ArticleId IdType="pubmed">34754112</ArticleId></ArticleIdList></Reference><Reference><Citation>Aboy M., Liddell K., Jordan M., Crespo C., Liddicoat J. European Patent Protection for Medical Uses of Known Products and Drug Repurposing. Nat. Biotechnol. 2022;40:465–471. doi: 10.1038/s41587-022-01269-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-022-01269-3</ArticleId><ArticleId IdType="pubmed">35418638</ArticleId></ArticleIdList></Reference><Reference><Citation>Seymore S. Patenting New Uses for Old Inventions. Vanderbilt Law Rev. 2020;73:479.</Citation></Reference><Reference><Citation>Center for Veterinary Medicine  Generic Animal Drug and Patent Term Restoration Act (GADPTRA). FDA 2024.  [(accessed on 26 July 2024)]; Available online:  https://www.fda.gov/animal-veterinary/guidance-regulations/generic-animal-drug-and-patent-term-restoration-act-gadptra.</Citation></Reference><Reference><Citation>Gould J.M. An Overview of Patent Law as Applied to the Field of Veterinary Medicine. AAPS J. 2008;10:1–8. doi: 10.1208/s12248-007-9005-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/s12248-007-9005-4</ArticleId><ArticleId IdType="pmc">PMC2751450</ArticleId><ArticleId IdType="pubmed">18446500</ArticleId></ArticleIdList></Reference><Reference><Citation>Ribeiro S. Presentation—Data Exclusivity, Market Protection, Orphan and Paediatric Rewards.  [(accessed on 26 July 2024)].  Available online:  https://www.ema.europa.eu/en/search?search_api_fulltext=orphan%20and%20paediatric%20rewards%20&amp;f%5B0%5D=ema_search_entity_is_document%3ADocument.</Citation></Reference><Reference><Citation>Exclusivity and Generic Drugs: What Does It Mean?  [(accessed on 26 July 2024)]; Available online:  https://www.fda.gov/search?s=Exclusivity+and+Generic+Drugs%3A+What+Does+It+Mean%3F.</Citation></Reference><Reference><Citation>Franco P. Orphan Drugs: The Regulatory Environment. Drug Discov. Today. 2013;18:163–172. doi: 10.1016/j.drudis.2012.08.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2012.08.009</ArticleId><ArticleId IdType="pubmed">22981668</ArticleId></ArticleIdList></Reference><Reference><Citation>Orphan Designation: Overview|European Medicines Agency.  [(accessed on 26 July 2024)].  Available online:  https://www.ema.europa.eu/en/human-regulatory-overview/orphan-designation-overview.</Citation></Reference><Reference><Citation>Jonker A.H., O’Connor D., Cavaller-Bellaubi M., Fetro C., Gogou M., ’T Hoen P.A.C., de Kort M., Stone H., Valentine N., Pasmooij A.M.G. Drug Repurposing for Rare: Progress and Opportunities for the Rare Disease Community. Front. Med. 2024;11:1352803. doi: 10.3389/fmed.2024.1352803.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2024.1352803</ArticleId><ArticleId IdType="pmc">PMC10828010</ArticleId><ArticleId IdType="pubmed">38298814</ArticleId></ArticleIdList></Reference><Reference><Citation>Center for Veterinary Medicine  Minor Use/Minor Species.  [(accessed on 26 July 2024)]; Available online:  https://www.fda.gov/animal-veterinary/development-approval-process/minor-useminor-species.</Citation></Reference><Reference><Citation>Fetro C., Scherman D. Drug Repurposing in Rare Diseases: Myths and Reality. Therapie. 2020;75:157–160. doi: 10.1016/j.therap.2020.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.therap.2020.02.006</ArticleId><ArticleId IdType="pubmed">32241561</ArticleId></ArticleIdList></Reference><Reference><Citation>Hechtelt Jonker A., Day S., Gabaldo M., Stone H., de Kort M., O’Connor D.J., Pasmooij A.M.G. IRDiRC Drug Repurposing Guidebook: Making Better Use of Existing Drugs to Tackle Rare Diseases. Nat. Rev. Drug Discov. 2023;22:937–938. doi: 10.1038/d41573-023-00168-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41573-023-00168-9</ArticleId><ArticleId IdType="pubmed">37872324</ArticleId></ArticleIdList></Reference><Reference><Citation>Avram S., Wilson T.B., Curpan R., Halip L., Borota A., Bora A., Bologa C.G., Holmes J., Knockel J., Yang J.J., et al. DrugCentral 2023 Extends Human Clinical Data and Integrates Veterinary Drugs. Nucleic Acids Res. 2023;51:D1276–D1287. doi: 10.1093/nar/gkac1085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkac1085</ArticleId><ArticleId IdType="pmc">PMC9825566</ArticleId><ArticleId IdType="pubmed">36484092</ArticleId></ArticleIdList></Reference><Reference><Citation>Center for Veterinary Medicine  The Ins and Outs of Extra-Label Drug Use in Animals: A Resource for Veterinarians. FDA 2023.  [(accessed on 26 July 2024)]; Available online:  https://www.fda.gov/animal-veterinary/resources-you/ins-and-outs-extra-label-drug-use-animals-resource-veterinarians.</Citation></Reference><Reference><Citation>Regulation (EU) 2019/6 of the European Parliament and of the Council of 11 December 2018 on Veterinary Medicinal Products and Repealing Directive 2001/82/EC (Text with EEA Relevance); Volume 004. 2018.  [(accessed on 30 July 2024)].  Available online:  https://eur-lex.europa.eu/eli/reg/2019/6/oj.</Citation></Reference><Reference><Citation>Drug Approval Package.  [(accessed on 30 July 2024)]; Available online:  https://www.accessdata.fda.gov/drugsatfda_docs/NDA/98/viagra/viagra_toc.cfm.</Citation></Reference><Reference><Citation>Revatio (Sildenafil Citrate) FDA Approval History.  [(accessed on 30 July 2024)].  Available online:  https://www.drugs.com/history/revatio.html.</Citation></Reference><Reference><Citation>Center for Veterinary Medicine  FDA Proposes New Regulations for Animal Drug Labeling. FDA 2024.  [(accessed on 26 July 2024)]; Available online:  https://www.fda.gov/animal-veterinary/cvm-updates/fda-proposes-new-regulations-animal-drug-labeling.</Citation></Reference><Reference><Citation>Novo Nordisk Ascent: Will Europe’s Biggest Company Continue to Soar?  [(accessed on 26 July 2024)].  Available online:  https://www.euronews.com/business/2023/12/05/novo-nordisk-ascent-will-europes-biggest-company-continue-to-soar.</Citation></Reference><Reference><Citation>Is Semaglutide the “New Statin”? Not So Fast.  [(accessed on 26 July 2024)].  Available online:  https://www.medscape.com/viewarticle/semaglutide-new-statin-not-so-fast-2024a1000ade?ecd=mkm_ret_240623_mscpmrk-OUS_InFocus_etid6609727&amp;uac=427892HG&amp;impID=6609727.</Citation></Reference><Reference><Citation>Types of Cancer.  [(accessed on 26 July 2024)].  Available online:  https://www.cancerresearchuk.org/about-cancer/what-is-cancer/how-cancer-starts/types-of-cancer.</Citation></Reference><Reference><Citation>IARC . IARC Biennial Report 2022–2023. International Agency for Research on Cancer; Lyon, France: 2023.</Citation></Reference><Reference><Citation>GLOBOCAN 2022: Latest Global Cancer Data Shows Rising Incidence and Stark Inequities|UICC.  [(accessed on 26 July 2024)].  Available online:  https://www.uicc.org/news/globocan-2022-latest-global-cancer-data-shows-rising-incidence-and-stark-inequities.</Citation></Reference><Reference><Citation>Veterinary Oncology Market Analysis by Radiology, Chemotherapy, Combination Therapy, Immunotherapy, and Targeted Therapy from 2023 to 2033.  [(accessed on 26 July 2024)].  Available online:  https://www.factmr.com/report/veterinary-oncology-market.</Citation></Reference><Reference><Citation>Jassim A., Rahrmann E.P., Simons B.D., Gilbertson R.J. Cancers Make Their Own Luck: Theories of Cancer Origins. Nat. Rev. Cancer. 2023;23:710–724. doi: 10.1038/s41568-023-00602-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41568-023-00602-5</ArticleId><ArticleId IdType="pubmed">37488363</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh J.H., Cho J.-Y. Comparative Oncology: Overcoming Human Cancer through Companion Animal Studies. Exp. Mol. Med. 2023;55:725–734. doi: 10.1038/s12276-023-00977-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-023-00977-3</ArticleId><ArticleId IdType="pmc">PMC10167357</ArticleId><ArticleId IdType="pubmed">37009802</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiffman J.D., Breen M. Comparative Oncology: What Dogs and Other Species Can Teach Us about Humans with Cancer. Philos. Trans. R. Soc. B Biol. Sci. 2015;370:20140231. doi: 10.1098/rstb.2014.0231.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rstb.2014.0231</ArticleId><ArticleId IdType="pmc">PMC4581033</ArticleId><ArticleId IdType="pubmed">26056372</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss M.C., Eulo V., Van Tine B.A. Truly Man’s Best Friend: Canine Cancers Drive Drug Repurposing in Osteosarcoma. Clin. Cancer Res. 2022;28:571–572. doi: 10.1158/1078-0432.CCR-21-3471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-21-3471</ArticleId><ArticleId IdType="pubmed">34880110</ArticleId></ArticleIdList></Reference><Reference><Citation>About Biomarkers and Qualification. FDA 2024.  [(accessed on 26 July 2024)]; Available online:  https://www.fda.gov/drugs/biomarker-qualification-program/about-biomarkers-and-qualification.</Citation></Reference><Reference><Citation>Kang K.N., Koh E.Y., Jang J.Y., Kim C.W. Multiple Biomarkers Are More Accurate than a Combination of Carbohydrate Antigen 125 and Human Epididymis Protein 4 for Ovarian Cancer Screening. Obstet. Gynecol. Sci. 2022;65:346–354. doi: 10.5468/ogs.22017.</Citation><ArticleIdList><ArticleId IdType="doi">10.5468/ogs.22017</ArticleId><ArticleId IdType="pmc">PMC9304440</ArticleId><ArticleId IdType="pubmed">35443557</ArticleId></ArticleIdList></Reference><Reference><Citation>Kao C., Powers E., Wu Y., Datto M.B., Green M.F., Strickler J.H., Ready N.E., Zhang T., Clarke J.M. Predictive Value of Combining Biomarkers for Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. Clin. Lung Cancer. 2021;22:500–509. doi: 10.1016/j.cllc.2021.03.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cllc.2021.03.017</ArticleId><ArticleId IdType="pubmed">33972172</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliver A., Greenberg C.C. Measuring Outcomes in Oncology Treatment: The Importance of Patient-Centered Outcomes. Surg. Clin. N. Am. 2009;89:17–25. doi: 10.1016/j.suc.2008.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.suc.2008.09.015</ArticleId><ArticleId IdType="pmc">PMC4539252</ArticleId><ArticleId IdType="pubmed">19186228</ArticleId></ArticleIdList></Reference><Reference><Citation>Market Research Future  Market Research Future: Industry Analysis Report, Business Consulting and Research.  [(accessed on 26 July 2024)].  Available online:  https://www.marketresearchfuture.com.</Citation></Reference><Reference><Citation>Pet Cancer Therapeutics Market Size &amp; Share Report, 2023–2032.  [(accessed on 26 July 2024)].  Available online:  https://www.gminsights.com/industry-analysis/pet-cancer-therapeutics-market.</Citation></Reference><Reference><Citation>Ursu O., Holmes J., Knockel J., Bologa C.G., Yang J.J., Mathias S.L., Nelson S.J., Oprea T.I. DrugCentral: Online Drug Compendium. Nucleic Acids Res. 2017;45:D932–D939. doi: 10.1093/nar/gkw993.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkw993</ArticleId><ArticleId IdType="pmc">PMC5210665</ArticleId><ArticleId IdType="pubmed">27789690</ArticleId></ArticleIdList></Reference><Reference><Citation>Center for Veterinary Medicine  Approved Animal Drug Products (Green Book)  [(accessed on 26 July 2024)]; Available online:  https://www.fda.gov/animal-veterinary/products/approved-animal-drug-products-green-book.</Citation></Reference><Reference><Citation>Klingemann H. Immunotherapy for Dogs: Running Behind Humans. Front. Immunol. 2018;9:133. doi: 10.3389/fimmu.2018.00133.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00133</ArticleId><ArticleId IdType="pmc">PMC5807660</ArticleId><ArticleId IdType="pubmed">29459862</ArticleId></ArticleIdList></Reference><Reference><Citation>Biller B., Berg J., Garrett L., Ruslander D., Wearing R., Abbott B., Patel M., Smith D., Bryan C. 2016 AAHA Oncology Guidelines for Dogs and Cats. J. Am. Anim. Hosp. Assoc. 2016;52:181–204. doi: 10.5326/JAAHA-MS-6570.</Citation><ArticleIdList><ArticleId IdType="doi">10.5326/JAAHA-MS-6570</ArticleId><ArticleId IdType="pubmed">27259020</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfarouk K.O., Stock C.-M., Taylor S., Walsh M., Muddathir A.K., Verduzco D., Bashir A.H.H., Mohammed O.Y., Elhassan G.O., Harguindey S., et al. Resistance to Cancer Chemotherapy: Failure in Drug Response from ADME to P-Gp. Cancer Cell Int. 2015;15:71. doi: 10.1186/s12935-015-0221-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12935-015-0221-1</ArticleId><ArticleId IdType="pmc">PMC4502609</ArticleId><ArticleId IdType="pubmed">26180516</ArticleId></ArticleIdList></Reference><Reference><Citation>Klopfleisch R., Kohn B., Gruber A.D. Mechanisms of Tumour Resistance against Chemotherapeutic Agents in Veterinary Oncology. Vet. J. 2016;207:63–72. doi: 10.1016/j.tvjl.2015.06.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tvjl.2015.06.015</ArticleId><ArticleId IdType="pubmed">26526523</ArticleId></ArticleIdList></Reference><Reference><Citation>Zandvliet M., Teske E. Mechanisms of Drug Resistance in Veterinary Oncology—A Review with an Emphasis on Canine Lymphoma. Vet. Sci. 2015;2:150–184. doi: 10.3390/vetsci2030150.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vetsci2030150</ArticleId><ArticleId IdType="pmc">PMC5644636</ArticleId><ArticleId IdType="pubmed">29061939</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Zhang H., Chen X. Drug Resistance and Combating Drug Resistance in Cancer. Cancer Drug Resist. 2019;2:141–160. doi: 10.20517/cdr.2019.10.</Citation><ArticleIdList><ArticleId IdType="doi">10.20517/cdr.2019.10</ArticleId><ArticleId IdType="pmc">PMC8315569</ArticleId><ArticleId IdType="pubmed">34322663</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim G.-H., An J.-H., Park S.-M., Youn G.-H., Oh Y.-I., Seo K.-W., Youn H.-Y. Macrophage Induces Anti-Cancer Drug Resistance in Canine Mammary Gland Tumor Spheroid. Sci. Rep. 2023;13:10394. doi: 10.1038/s41598-023-37311-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-37311-w</ArticleId><ArticleId IdType="pmc">PMC10300191</ArticleId><ArticleId IdType="pubmed">37369757</ArticleId></ArticleIdList></Reference><Reference><Citation>Karthika C., Sureshkumar R., Zehravi M., Akter R., Ali F., Ramproshad S., Mondal B., Tagde P., Ahmed Z., Khan F.S., et al. Multidrug Resistance of Cancer Cells and the Vital Role of P-Glycoprotein. Life. 2022;12:897. doi: 10.3390/life12060897.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life12060897</ArticleId><ArticleId IdType="pmc">PMC9227591</ArticleId><ArticleId IdType="pubmed">35743927</ArticleId></ArticleIdList></Reference><Reference><Citation>Mealey K.L., Fidel J. P-Glycoprotein Mediated Drug Interactions in Animals and Humans with Cancer. J. Vet. Intern. Med. 2015;29:1–6. doi: 10.1111/jvim.12525.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jvim.12525</ArticleId><ArticleId IdType="pmc">PMC4858061</ArticleId><ArticleId IdType="pubmed">25619511</ArticleId></ArticleIdList></Reference><Reference><Citation>Gramer I., Leidolf R., Döring B., Klintzsch S., Krämer E.-M., Yalcin E., Petzinger E., Geyer J. Breed Distribution of the Nt230(Del4) MDR1 Mutation in Dogs. Vet. J. 2011;189:67–71. doi: 10.1016/j.tvjl.2010.06.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tvjl.2010.06.012</ArticleId><ArticleId IdType="pubmed">20655253</ArticleId></ArticleIdList></Reference><Reference><Citation>Maddison J.E., Page S.W. Chapter 3—Adverse Drug Reactions. In: Maddison J.E., Page S.W., Church D.B., editors. Small Animal Clinical Pharmacology (Second Edition) W.B. Saunders; Edinburgh, UK: 2008. pp. 41–58.</Citation></Reference><Reference><Citation>Moses L., Niemi S., Karlsson E. Pet Genomics Medicine Runs Wild. Nature. 2018;559:470–472. doi: 10.1038/d41586-018-05771-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-018-05771-0</ArticleId><ArticleId IdType="pubmed">30046086</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu K., Rodrigues L., Post G., Harvey G., White M., Miller A., Lambert L., Lewis B., Lopes C., Zou J. Analyses of Canine Cancer Mutations and Treatment Outcomes Using Real-World Clinico-Genomics Data of 2119 Dogs. NPJ Precis. Oncol. 2023;7:8. doi: 10.1038/s41698-023-00346-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41698-023-00346-3</ArticleId><ArticleId IdType="pmc">PMC9852553</ArticleId><ArticleId IdType="pubmed">36658200</ArticleId></ArticleIdList></Reference><Reference><Citation>Chon E., Sakthikumar S., Tang M., Hamilton M.J., Vaughan A., Smith A., Sommer B., Robat C., Manley C., Mullin C., et al. Novel Genomic Prognostic Biomarkers for Dogs with Cancer. J. Vet. Intern. Med. 2023;37:2410–2421. doi: 10.1111/jvim.16893.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jvim.16893</ArticleId><ArticleId IdType="pmc">PMC10658597</ArticleId><ArticleId IdType="pubmed">37801037</ArticleId></ArticleIdList></Reference><Reference><Citation>Hezkiy E.E., Kumar S., Gahramanov V., Yaglom J., Hesin A., Jadhav S.S., Guzev E., Patel S., Avinery E., Firer M.A., et al. Search for Synergistic Drug Combinations to Treat Chronic Lymphocytic Leukemia. Cells. 2022;11:3671. doi: 10.3390/cells11223671.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11223671</ArticleId><ArticleId IdType="pmc">PMC9688317</ArticleId><ArticleId IdType="pubmed">36429097</ArticleId></ArticleIdList></Reference><Reference><Citation>Irie N., Mizoguchi K., Warita T., Nakano M., Sasaki K., Tashiro J., Osaki T., Ishikawa T., Oltvai Z.N., Warita K. Repurposing of the Cardiovascular Drug Statin for the Treatment of Cancers: Efficacy of Statin–Dipyridamole Combination Treatment in Melanoma Cell Lines. Biomedicines. 2024;12:698. doi: 10.3390/biomedicines12030698.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines12030698</ArticleId><ArticleId IdType="pmc">PMC10968169</ArticleId><ArticleId IdType="pubmed">38540310</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin H., Wang L., Bernards R. Rational Combinations of Targeted Cancer Therapies: Background, Advances and Challenges. Nat. Rev. Drug Discov. 2023;22:213–234. doi: 10.1038/s41573-022-00615-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-022-00615-z</ArticleId><ArticleId IdType="pubmed">36509911</ArticleId></ArticleIdList></Reference><Reference><Citation>Giuliano A., Horta R.S., Vieira R.A.M., Hume K.R., Dobson J. Repurposing Drugs in Small Animal Oncology. Animals. 2023;13:139. doi: 10.3390/ani13010139.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ani13010139</ArticleId><ArticleId IdType="pmc">PMC9817697</ArticleId><ArticleId IdType="pubmed">36611747</ArticleId></ArticleIdList></Reference><Reference><Citation>Vazquez E., Lipovka Y., Cervantes-Arias A., Garibay-Escobar A., Haby M.M., Queiroga F.L., Velazquez C. Canine Mammary Cancer: State of the Art and Future Perspectives. Animals. 2023;13:3147. doi: 10.3390/ani13193147.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ani13193147</ArticleId><ArticleId IdType="pmc">PMC10571550</ArticleId><ArticleId IdType="pubmed">37835752</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu T.-W., Yamamoto H., Morita S., Fukushima R., Elbadawy M., Usui T., Sasaki K. Comparative Pharmacokinetics of Tyrosine Kinase Inhibitor, Lapatinib, in Dogs and Cats Following Single Oral Administration. J. Vet. Med. Sci. 2024;86:317–321. doi: 10.1292/jvms.23-0448.</Citation><ArticleIdList><ArticleId IdType="doi">10.1292/jvms.23-0448</ArticleId><ArticleId IdType="pmc">PMC10963087</ArticleId><ArticleId IdType="pubmed">38281758</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao P., Knaus E.E. Evolution of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Cyclooxygenase (COX) Inhibition and Beyond. J. Pharm. Pharm. Sci. 2008;11:81s–110s. doi: 10.18433/J3T886.</Citation><ArticleIdList><ArticleId IdType="doi">10.18433/J3T886</ArticleId><ArticleId IdType="pubmed">19203472</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi T., Kozaki K., Yatabe Y., Achiwa H., Hida T. Increased Expression of COX-2 in the Development of Human Lung Cancers. JEP(T) 2002;21:21.2. doi: 10.1615/JEnvironPatholToxicolOncol.v21.i2.110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1615/JEnvironPatholToxicolOncol.v21.i2.110</ArticleId><ArticleId IdType="pubmed">12086404</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricciotti E., FitzGerald G.A. Prostaglandins and Inflammation. Arterioscler. Thromb. Vasc. Biol. 2011;31:986–1000. doi: 10.1161/ATVBAHA.110.207449.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.110.207449</ArticleId><ArticleId IdType="pmc">PMC3081099</ArticleId><ArticleId IdType="pubmed">21508345</ArticleId></ArticleIdList></Reference><Reference><Citation>Pountos I., Georgouli T., Bird H., Giannoudis P.V. Nonsteroidal Anti-Inflammatory Drugs: Prostaglandins, Indications, and Side Effects. Int. J. Interferon Cytokine Mediat. Res. 2011;3:19–27. doi: 10.2147/IJICMR.S10200.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJICMR.S10200</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuno H., Sakamoto C., Matsuda K., Wada K., Uchida T., Noguchi H., Akamatsu T., Kasuga M. Induction of Cyclooxygenase 2 in Gastric Mucosal Lesions and Its Inhibition by the Specific Antagonist Delays Healing in Mice. Gastroenterology. 1997;112:387–397. doi: 10.1053/gast.1997.v112.pm9024292.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/gast.1997.v112.pm9024292</ArticleId><ArticleId IdType="pubmed">9024292</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Ding E.L., Song Y. Adverse Effects of Cyclooxygenase 2 Inhibitors on Renal and Arrhythmia Events: Meta-Analysis of Randomized Trials. JAMA. 2006;296:1619–1632. doi: 10.1001/jama.296.13.jrv60015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.296.13.jrv60015</ArticleId><ArticleId IdType="pubmed">16968832</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson K.L., Zulch H., O’Neill D.G., Meeson R.L., Collins L.M. Risk Factors for Canine Osteoarthritis and Its Predisposing Arthropathies: A Systematic Review. Front. Vet. Sci. 2020;7:220. doi: 10.3389/fvets.2020.00220.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fvets.2020.00220</ArticleId><ArticleId IdType="pmc">PMC7198754</ArticleId><ArticleId IdType="pubmed">32411739</ArticleId></ArticleIdList></Reference><Reference><Citation>Previcox|European Medicines Agency.  [(accessed on 26 July 2024)].  Available online:  https://www.ema.europa.eu/en/medicines/veterinary/EPAR/previcox#authorisation-details.</Citation></Reference><Reference><Citation>Trocoxil|European Medicines Agency.  [(accessed on 26 July 2024)].  Available online:  https://www.ema.europa.eu/en/medicines/veterinary/EPAR/trocoxil#authorisation-details.</Citation></Reference><Reference><Citation>Onsior|European Medicines Agency.  [(accessed on 26 July 2024)].  Available online:  https://www.ema.europa.eu/en/medicines/veterinary/EPAR/onsior#authorisation-details.</Citation></Reference><Reference><Citation>Cimalgex|European Medicines Agency.  [(accessed on 26 July 2024)].  Available online:  https://www.ema.europa.eu/en/medicines/veterinary/EPAR/cimalgex.</Citation></Reference><Reference><Citation>Deramaxx Receives FDA Approval for Canine Osteoarthritis.  [(accessed on 26 July 2024)].  Available online:  https://www.dvm360.com/view/deramaxx-receives-fda-approval-canine-osteoarthritis.</Citation></Reference><Reference><Citation>Daxocox|European Medicines Agency.  [(accessed on 26 July 2024)].  Available online:  https://www.ema.europa.eu/en/medicines/veterinary/EPAR/daxocox#authorisation-details.</Citation></Reference><Reference><Citation>Botha J.H., Robinson K.M., Ramchurren N., Reddi K., Norman R.J. Human Esophageal Carcinoma Cell Lines: Prostaglandin Production, Biological Properties, and Behavior in Nude Mice23. JNCI J. Natl. Cancer Inst. 1986;76:1053–1056. doi: 10.1093/jnci/76.6.1053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/76.6.1053</ArticleId><ArticleId IdType="pubmed">3458943</ArticleId></ArticleIdList></Reference><Reference><Citation>Jara-Gutiérrez Á., Baladrón V. The Role of Prostaglandins in Different Types of Cancer. Cells. 2021;10:1487. doi: 10.3390/cells10061487.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10061487</ArticleId><ArticleId IdType="pmc">PMC8231512</ArticleId><ArticleId IdType="pubmed">34199169</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P., He D., Song E., Jiang M., Song Y. Celecoxib Enhances the Sensitivity of Non-Small-Cell Lung Cancer Cells to Radiation-Induced Apoptosis through Downregulation of the Akt/mTOR Signaling Pathway and COX-2 Expression. PLoS ONE. 2019;14:e0223760. doi: 10.1371/journal.pone.0223760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0223760</ArticleId><ArticleId IdType="pmc">PMC6793859</ArticleId><ArticleId IdType="pubmed">31613929</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen B., Wei Y.-T., Mu L.-L., Wen G.-R., Zhao K. The Molecular Mechanisms of Celecoxib in Tumor Development. Medicine. 2020;99:e22544. doi: 10.1097/MD.0000000000022544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000022544</ArticleId><ArticleId IdType="pmc">PMC7535670</ArticleId><ArticleId IdType="pubmed">33019464</ArticleId></ArticleIdList></Reference><Reference><Citation>Curry J.M., Besmer D.M., Erick T.K., Steuerwald N., Roy L.D., Grover P., Rao S., Nath S., Ferrier J.W., Reid R.W., et al. Indomethacin Enhances Anti-Tumor Efficacy of a MUC1 Peptide Vaccine against Breast Cancer in MUC1 Transgenic Mice. PLoS ONE. 2019;14:e0224309. doi: 10.1371/journal.pone.0224309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0224309</ArticleId><ArticleId IdType="pmc">PMC6834267</ArticleId><ArticleId IdType="pubmed">31693710</ArticleId></ArticleIdList></Reference><Reference><Citation>Karai E., Szebényi K., Windt T., Fehér S., Szendi E., Dékay V., Vajdovich P., Szakács G., Füredi A. Celecoxib Prevents Doxorubicin-Induced Multidrug Resistance in Canine and Mouse Lymphoma Cell Lines. Cancers. 2020;12:1117. doi: 10.3390/cancers12051117.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers12051117</ArticleId><ArticleId IdType="pmc">PMC7280963</ArticleId><ArticleId IdType="pubmed">32365663</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel V.A., Dunn M.J., Sorokin A. Regulation of MDR-1 (P-Glycoprotein) by Cyclooxygenase-2. J. Biol. Chem. 2002;277:38915–38920. doi: 10.1074/jbc.M206855200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M206855200</ArticleId><ArticleId IdType="pubmed">12138126</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu K., Fukuda K., Xing F., Zhang Y., Sharma S., Liu Y., Chan M.D., Zhou X., Qasem S.A., Pochampally R., et al. Roles of the Cyclooxygenase 2 Matrix Metalloproteinase 1 Pathway in Brain Metastasis of Breast Cancer. J. Biol. Chem. 2015;290:9842–9854. doi: 10.1074/jbc.M114.602185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.602185</ArticleId><ArticleId IdType="pmc">PMC4392281</ArticleId><ArticleId IdType="pubmed">25691572</ArticleId></ArticleIdList></Reference><Reference><Citation>Pannunzio A., Coluccia M. Cyclooxygenase-1 (COX-1) and COX-1 Inhibitors in Cancer: A Review of Oncology and Medicinal Chemistry Literature. Pharmaceuticals. 2018;11:101. doi: 10.3390/ph11040101.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph11040101</ArticleId><ArticleId IdType="pmc">PMC6316056</ArticleId><ArticleId IdType="pubmed">30314310</ArticleId></ArticleIdList></Reference><Reference><Citation>Search|European Medicines Agency (EMA)  [(accessed on 30 July 2024)].  Available online:  https://www.ema.europa.eu/en/search.</Citation></Reference><Reference><Citation>Center for Veterinary Medicine  Get the Facts about Pain Relievers for Pets. FDA 2022.  [(accessed on 30 July 2024)]; Available online:  https://www.fda.gov/animal-veterinary/animal-health-literacy/get-facts-about-pain-relievers-pets.</Citation></Reference><Reference><Citation>Atiportal.  [(accessed on 30 July 2024)]; Available online:  https://atiportal.nebih.gov.hu/moengallatgykesz.html.</Citation></Reference><Reference><Citation>Silva I.C., Maia C.A.A., Raymundo A.C., Prata M.N.L., Romero T.R.L., Duarte I.D.G., Manrique W.G., Perez A.C., Belo M.A.A. Meta-Analysis of the Therapeutic Use of Dipyrone in Dogs: Pharmacological Effects and Clinical Safety. Ars Vet. 2021;37:21–30. doi: 10.15361/2175-0106.2021v37n1p21-30.</Citation><ArticleIdList><ArticleId IdType="doi">10.15361/2175-0106.2021v37n1p21-30</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandrasekharan N.V., Dai H., Roos K.L.T., Evanson N.K., Tomsik J., Elton T.S., Simmons D.L. COX-3, a Cyclooxygenase-1 Variant Inhibited by Acetaminophen and Other Analgesic/Antipyretic Drugs: Cloning, Structure, and Expression. Proc. Natl. Acad. Sci. USA. 2002;99:13926–13931. doi: 10.1073/pnas.162468699.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.162468699</ArticleId><ArticleId IdType="pmc">PMC129799</ArticleId><ArticleId IdType="pubmed">12242329</ArticleId></ArticleIdList></Reference><Reference><Citation>Streppa H.K., Jones C.J., Budsberg S.C. Cyclooxygenase Selectivity of Nonsteroidal Anti-Inflammatory Drugs in Canine Blood. Am. J. Vet. Res. 2002;63:91–94. doi: 10.2460/AJVR.2002.63.91.</Citation><ArticleIdList><ArticleId IdType="doi">10.2460/AJVR.2002.63.91</ArticleId><ArticleId IdType="pubmed">16206787</ArticleId></ArticleIdList></Reference><Reference><Citation>Gierse J.K., Staten N.R., Casperson G.F., Koboldt C.M., Trigg J.S., Reitz B.A., Pierce J.L., Seibert K. Cloning, Expression, and Selective Inhibition of Canine Cyclooxygenase-1 and Cyclooxygenase-2. Vet. Ther. 2002;3:270–280.</Citation><ArticleIdList><ArticleId IdType="pubmed">12447834</ArticleId></ArticleIdList></Reference><Reference><Citation>Brideau C., Staden C.V., Chan C.C. In Vitro Effects of Cyclooxygenase Inhibitors in Whole Blood of Horses, Dogs, and Cats. Am. J. Vet. Res. 2001;62:1755–1760. doi: 10.2460/ajvr.2001.62.1755.</Citation><ArticleIdList><ArticleId IdType="doi">10.2460/ajvr.2001.62.1755</ArticleId><ArticleId IdType="pubmed">11703020</ArticleId></ArticleIdList></Reference><Reference><Citation>Kay-Mugford P. In Vitro Evaluation of the Effects of Nonsteroidal Anti-Inflammatory Drugs on Cyclooxygenase-1 and -2 in the Dog. University of Guelph; Guelph, ON, Canada: 1999.</Citation></Reference><Reference><Citation>Kay-Mugford P., Benn S.J., LaMarre J., Conlon P. In Vitro Effects of Nonsteroidal Anti-Inflammatory Drugs on Cyclooxygenase Activity in Dogs. Am. J. Vet. Res. 2000;61:802–810. doi: 10.2460/ajvr.2000.61.802.</Citation><ArticleIdList><ArticleId IdType="doi">10.2460/ajvr.2000.61.802</ArticleId><ArticleId IdType="pubmed">10895904</ArticleId></ArticleIdList></Reference><Reference><Citation>Vane J.R., Botting R.M. New Insights into the Mode of Action of Anti-Inflammatory Drugs. Inflamm. Res. 1995;44:1–10. doi: 10.1007/BF01630479.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01630479</ArticleId><ArticleId IdType="pubmed">7664022</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricketts A.P., Lundy K.M., Seibel S.B. Evaluation of Selective Inhibition of Canine Cyclooxygenase 1 and 2 by Carprofen and Other Nonsteroidal Anti-Inflammatory Drugs. Am. J. Vet. Res. 1998;59:1441–1446. doi: 10.2460/ajvr.1998.59.11.1441.</Citation><ArticleIdList><ArticleId IdType="doi">10.2460/ajvr.1998.59.11.1441</ArticleId><ArticleId IdType="pubmed">9829404</ArticleId></ArticleIdList></Reference><Reference><Citation>McCann M.E., Andersen D.R., Zhang D., Brideau C., Black W.C., Hanson P.D., Hickey G.J. In Vitro Effects and in Vivo Efficacy of a Novel Cyclooxygenase-2 Inhibitor in Dogs with Experimentally Induced Synovitis. Am. J. Vet. Res. 2004;65:503–512. doi: 10.2460/ajvr.2004.65.503.</Citation><ArticleIdList><ArticleId IdType="doi">10.2460/ajvr.2004.65.503</ArticleId><ArticleId IdType="pubmed">15077695</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson J.E., Chandrasekharan N.V., Westover K.D., Eager K.B., Simmons D.L. Determination of Expression of Cyclooxygenase-1 and -2 Isozymes in Canine Tissues and Their Differential Sensitivity to Nonsteroidal Anti-Inflammatory Drugs. Am. J. Vet. Res. 2004;65:810–818. doi: 10.2460/ajvr.2004.65.810.</Citation><ArticleIdList><ArticleId IdType="doi">10.2460/ajvr.2004.65.810</ArticleId><ArticleId IdType="pubmed">15198222</ArticleId></ArticleIdList></Reference><Reference><Citation>Lees P., Landoni M.F., Armstrong S., Frean S. New Insights into Inflammation with Particular Reference to the Role of COX Enzymes; Proceedings of the 8th International Congress of the European Association for Veterinary Pharmacology and Toxicology; Jerusalem, Israel. 30 July–3 August 2000.</Citation></Reference><Reference><Citation>King J.N., Rudaz C., Borer L., Jung M., Seewald W., Lees P. In Vitro and Ex Vivo Inhibition of Canine Cyclooxygenase Isoforms by Robenacoxib: A Comparative Study. Res. Vet. Sci. 2010;88:497–506. doi: 10.1016/j.rvsc.2009.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rvsc.2009.11.002</ArticleId><ArticleId IdType="pubmed">20004922</ArticleId></ArticleIdList></Reference><Reference><Citation>Giraudel J., Toutain P.-L., Lees P. Development of in Vitro Assays for the Evaluation of Cyclooxygenase Inhibitors and Application for Predicting the Selectivity of NSAIDs in the Cat. Am. J. Vet. Res. 2005;66:700–709. doi: 10.2460/ajvr.2005.66.700.</Citation><ArticleIdList><ArticleId IdType="doi">10.2460/ajvr.2005.66.700</ArticleId><ArticleId IdType="pubmed">15900953</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmid V.B., Seewald W., Lees P., King J.N. In Vitro and Ex Vivo Inhibition of COX Isoforms by Robenacoxib in the Cat: A Comparative Study. J. Vet. Pharmacol. Ther. 2010;33:444–452. doi: 10.1111/j.1365-2885.2010.01166.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2885.2010.01166.x</ArticleId><ArticleId IdType="pubmed">20840388</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelligand L., King J.N., Hormazabal V., Toutain P.L., Elliott J., Lees P. Differential Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modelling of Robenacoxib and Ketoprofen in a Feline Model of Inflammation. J. Vet. Pharmacol. Ther. 2014;37:354–366. doi: 10.1111/jvp.12107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jvp.12107</ArticleId><ArticleId IdType="pubmed">24628410</ArticleId></ArticleIdList></Reference><Reference><Citation>Wibberley A., McCafferty G.P., Evans C., Edwards R.M., Hieble J.P. Dual, but Not Selective, COX-1 and COX-2 Inhibitors, Attenuate Acetic Acid-Evoked Bladder Irritation in the Anaesthetised Female Cat. Br. J. Pharmacol. 2006;148:154–161. doi: 10.1038/sj.bjp.0706715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjp.0706715</ArticleId><ArticleId IdType="pmc">PMC1617054</ArticleId><ArticleId IdType="pubmed">16547526</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuniberti B., Odore R., Barbero R., Cagnardi P., Badino P., Girardi C., Re G. In Vitro and Ex Vivo Pharmacodynamics of Selected Non-Steroidal Anti-Inflammatory Drugs in Equine Whole Blood. Vet. J. 2012;191:327–333. doi: 10.1016/j.tvjl.2011.03.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tvjl.2011.03.016</ArticleId><ArticleId IdType="pubmed">21565533</ArticleId></ArticleIdList></Reference><Reference><Citation>Toutain P.L., Cester C.C., Haak T., Metge S. Pharmacokinetic Profile and in Vitro Selective Cyclooxygenase-2 Inhibition by Nimesulide in the Dog. J. Vet. Pharmacol. Ther. 2001;24:35–42. doi: 10.1046/j.1365-2885.2001.00303.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2885.2001.00303.x</ArticleId><ArticleId IdType="pubmed">11348485</ArticleId></ArticleIdList></Reference><Reference><Citation>Previcox|European Medicines Agency (EMA)  [(accessed on 30 July 2024)].  Available online:  https://www.ema.europa.eu/en/medicines/veterinary/EPAR/previcox.</Citation></Reference><Reference><Citation>Lees P., Pelligand L., Elliott J., Toutain P.-L., Michels G., Stegemann M. Pharmacokinetics, Pharmacodynamics, Toxicology and Therapeutics of Mavacoxib in the Dog: A Review. J. Vet. Pharmacol. Ther. 2015;38:1–14. doi: 10.1111/jvp.12185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jvp.12185</ArticleId><ArticleId IdType="pubmed">25413929</ArticleId></ArticleIdList></Reference><Reference><Citation>Lees P., Alexander-Bowman S., Hummel B., Kubiak T., Michels G., Krautmann M., Cox S., Toutain P.-L., Stegemann M. Pharmacokinetics and Pharmacodynamics of Mavacoxib in the Dog. 2009.  [(accessed on 30 July 2024)].  Available online:  https://www.researchgate.net/publication/295167267_Pharmacokinetics_and_pharmacodynamics_of_mavacoxib_in_the_dog.</Citation></Reference><Reference><Citation>Onsior|European Medicines Agency (EMA)  [(accessed on 30 July 2024)].  Available online:  https://www.ema.europa.eu/en/medicines/veterinary/EPAR/onsior.</Citation></Reference><Reference><Citation>Giraudel J.M., Toutain P.-L., King J.N., Lees P. Differential Inhibition of Cyclooxygenase Isoenzymes in the Cat by the NSAID Robenacoxib. J. Vet. Pharmacol. Ther. 2009;32:31–40. doi: 10.1111/j.1365-2885.2008.01031.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2885.2008.01031.x</ArticleId><ArticleId IdType="pubmed">19161453</ArticleId></ArticleIdList></Reference><Reference><Citation>Innes J., O’Neill T., Lascelles D. Use of Non-Steroidal Anti-Inflammatory Drugs for the Treatment of Canine Osteoarthritis. Practice. 2010;32:126–137. doi: 10.1136/inp.c1436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/inp.c1436</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelligand L., King J.N., Toutain P.L., Elliott J., Lees P. Pharmacokinetic/Pharmacodynamic Modelling of Robenacoxib in a Feline Tissue Cage Model of Inflammation. J. Vet. Pharmacol. Ther. 2012;35:19–32. doi: 10.1111/j.1365-2885.2011.01288.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2885.2011.01288.x</ArticleId><ArticleId IdType="pubmed">21767277</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagemakers M., van der Wal G.E., Cuberes R., Álvarez I., Andrés E.M., Buxens J., Vela J.M., Moorlag H., Mooij J.J.A., Molema G. COX-2 Inhibition Combined with Radiation Reduces Orthotopic Glioma Outgrowth by Targeting the Tumor Vasculature. Transl. Oncol. 2009;2:1–7. doi: 10.1593/tlo.08160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1593/tlo.08160</ArticleId><ArticleId IdType="pmc">PMC2647697</ArticleId><ArticleId IdType="pubmed">19252746</ArticleId></ArticleIdList></Reference><Reference><Citation>Cendrós J.-M., Salichs M., Encina G., Vela J.M., Homedes J.M. Pharmacology of Enflicoxib, a New Coxib Drug: Efficacy and Dose Determination by Clinical and Pharmacokinetic-Guided Approach for the Treatment of Osteoarthritis in Dogs Based on an Acute Arthritis Induction Model. Vet. Med. Sci. 2022;8:31–45. doi: 10.1002/vms3.670.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/vms3.670</ArticleId><ArticleId IdType="pmc">PMC8788976</ArticleId><ArticleId IdType="pubmed">34854245</ArticleId></ArticleIdList></Reference><Reference><Citation>Solà J., Menargues À., Homedes J., Salichs M., Álvarez I., Romero L., Vela J.M. Selective Inhibition of Cyclooxygenase-2 by Enflicoxib, Its Enantiomers and Its Main Metabolites in Vitro in Canine Blood. J. Vet. Pharmacol. Ther. 2022;45:235–244. doi: 10.1111/jvp.13042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jvp.13042</ArticleId><ArticleId IdType="pmc">PMC9306928</ArticleId><ArticleId IdType="pubmed">35038171</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang L.Y., Gatenby E.L., Kamida A., Whitelaw B.A., Hupp T.R., Argyle D.J. Global Gene Expression Analysis of Canine Osteosarcoma Stem Cells Reveals a Novel Role for COX-2 in Tumour Initiation. PLoS ONE. 2014;9:e83144. doi: 10.1371/journal.pone.0083144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0083144</ArticleId><ArticleId IdType="pmc">PMC3885401</ArticleId><ArticleId IdType="pubmed">24416158</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang L.Y., Argyle S.A., Kamida A., Morrison K.O., Argyle D.J. The Long-Acting COX-2 Inhibitor Mavacoxib (TrocoxilTM) Has Anti-Proliferative and pro-Apoptotic Effects on Canine Cancer Cell Lines and Cancer Stem Cells in Vitro. BMC Vet. Res. 2014;10:184. doi: 10.1186/s12917-014-0184-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12917-014-0184-9</ArticleId><ArticleId IdType="pmc">PMC4172958</ArticleId><ArticleId IdType="pubmed">25190452</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo K., Coh Y., Rebhun R.B., Ahn J., Han S.-M., Lee H., Youn H.-Y. Antitumor Effects of Celecoxib in COX-2 Expressing and Non-Expressing Canine Melanoma Cell Lines. Res. Vet. Sci. 2014;96:482–486. doi: 10.1016/j.rvsc.2014.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rvsc.2014.03.003</ArticleId><ArticleId IdType="pmc">PMC5021445</ArticleId><ArticleId IdType="pubmed">24656746</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathore K., Alexander M., Cekanova M. Piroxicam Inhibits Masitinib-Induced Cyclooxygenase 2 Expression in Oral Squamous Cell Carcinoma Cells in Vitro. Transl. Res. 2014;164:158–168. doi: 10.1016/j.trsl.2014.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2014.02.002</ArticleId><ArticleId IdType="pubmed">24631063</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T., Tamura D., Asano R. Usefulness of Selective COX-2 Inhibitors as Therapeutic Agents against Canine Mammary Tumors. Oncol. Rep. 2014;31:1637–1644. doi: 10.3892/or.2014.3010.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/or.2014.3010</ArticleId><ArticleId IdType="pubmed">24503782</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahidi R., Safi S., Farsinejad A., Panahi N. Citrate and Celecoxib Induce Apoptosis and Decrease Necrosis in Synergistic Manner in Canine Mammary Tumor Cells. Cell Mol. Biol. (Noisy-le-grand) 2015;61:22–28. doi: 10.14715/cmb/23.</Citation><ArticleIdList><ArticleId IdType="doi">10.14715/cmb/23</ArticleId><ArticleId IdType="pubmed">26475384</ArticleId></ArticleIdList></Reference><Reference><Citation>Arenas C., Peña L., Granados-Soler J.L., Pérez-Alenza M.D. Adjuvant Therapy for Highly Malignant Canine Mammary Tumours: Cox-2 Inhibitor versus Chemotherapy: A Case–Control Prospective Study. Vet. Rec. 2016;179:125. doi: 10.1136/vr.103398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/vr.103398</ArticleId><ArticleId IdType="pubmed">27377395</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshitake R., Saeki K., Watanabe M., Nakaoka N., Ong S.M., Hanafusa M., Choisunirachon N., Fujita N., Nishimura R., Nakagawa T. Molecular Investigation of the Direct Anti-Tumour Effects of Nonsteroidal Anti-Inflammatory Drugs in a Panel of Canine Cancer Cell Lines. Vet. J. 2017;221:38–47. doi: 10.1016/j.tvjl.2017.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tvjl.2017.02.001</ArticleId><ArticleId IdType="pubmed">28283079</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurst E.A., Pang L.Y., Argyle D.J. The Selective Cyclooxygenase-2 Inhibitor Mavacoxib (Trocoxil) Exerts Anti-Tumour Effects in Vitro Independent of Cyclooxygenase-2 Expression Levels. Vet. Comp. Oncol. 2019;17:194–207. doi: 10.1111/vco.12470.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/vco.12470</ArticleId><ArticleId IdType="pubmed">30767381</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso-Miguel D., Valdivia G., García-San José P., Alonso-Diez Á., Clares I., Portero M., Peña L., Pérez-Alenza M.D. Clinical Outcome of Dogs Diagnosed with Canine Inflammatory Mammary Cancer Treated with Metronomic Cyclophosphamide, a Cyclooxygenase-2 Inhibitor and Toceranib Phosphate. Vet. Comp. Oncol. 2022;20:179–188. doi: 10.1111/vco.12760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/vco.12760</ArticleId><ArticleId IdType="pubmed">34390295</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandi A., de Faria Lainetti P., Elias F., Rodrigues M.M.P., Fagundes Moraes L., Laufer-Amorim R., de Camargo L.S., Salles Gomes C.D.O.M., Fonseca-Alves C.E. Firocoxib as a Potential Neoadjuvant Treatment in Canine Patients with Triple-Negative Mammary Gland Tumors. Animals. 2023;13:60. doi: 10.3390/ani13010060.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ani13010060</ArticleId><ArticleId IdType="pmc">PMC9817520</ArticleId><ArticleId IdType="pubmed">36611669</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC about One Health.  [(accessed on 26 July 2024)]; Available online:  https://www.cdc.gov/one-health/about/index.html.</Citation></Reference><Reference><Citation>Zhu G., Yin J., Cuny G.D. Current Status and Challenges in Drug Discovery against the Globally Important Zoonotic Cryptosporidiosis. Anim. Dis. 2021;1:3. doi: 10.1186/s44149-021-00002-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s44149-021-00002-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroud C., Dmitriev I., Kashentseva E., Bryan J.N., Curiel D.T., Rindt H., Reinero C., Henry C.J., Bergman P.J., Mason N.J., et al. A One Health Overview, Facilitating Advances in Comparative Medicine and Translational Research. Clin. Transl. Med. 2016;5:26. doi: 10.1186/s40169-016-0107-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40169-016-0107-4</ArticleId><ArticleId IdType="pmc">PMC4996801</ArticleId><ArticleId IdType="pubmed">27558513</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie J.S., McKinnon M., Jeggo M. One Health: From Concept to Practice. In: Yamada A., Kahn L.H., Kaplan B., Monath T.P., Woodall J., Conti L., editors. Confronting Emerging Zoonoses: The One Health Paradigm. Springer; Tokyo, Japan: 2014. pp. 163–189.</Citation></Reference><Reference><Citation>Mackenzie J.S., Jeggo M. The One Health Approach—Why Is It So Important? Trop. Med. Infect. Dis. 2019;4:88. doi: 10.3390/tropicalmed4020088.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/tropicalmed4020088</ArticleId><ArticleId IdType="pmc">PMC6630404</ArticleId><ArticleId IdType="pubmed">31159338</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Pol K.H., Aljofan M., Blin O., Cornel J.H., Rongen G.A., Woestelandt A.-G., Spedding M. Drug Repurposing of Generic Drugs: Challenges and the Potential Role for Government. Appl. Health Econ. Health Policy. 2023;21:831–840. doi: 10.1007/s40258-023-00816-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40258-023-00816-6</ArticleId><ArticleId IdType="pmc">PMC10627937</ArticleId><ArticleId IdType="pubmed">37398987</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary E., Jackson M.J., Ledley F. Government as the First Investor in Biopharmaceutical Innovation: Evidence from New Drug Approvals 2010–2019. 2020.  [(accessed on 26 July 2024)].  Available online:  https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3731819.</Citation></Reference><Reference><Citation>Asker-Hagelberg C., Boran T., Bouygues C., Eskola S.M., Helmle L., Hernández C., Houýez F., Lee H., Lingri D.D., Louette L., et al. Repurposing of Medicines in the EU: Launch of a Pilot Framework. Front. Med. 2022;8:817663. doi: 10.3389/fmed.2021.817663.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.817663</ArticleId><ArticleId IdType="pmc">PMC8784735</ArticleId><ArticleId IdType="pubmed">35083258</ArticleId></ArticleIdList></Reference><Reference><Citation>One Health Drugs.  [(accessed on 30 July 2024)].  Available online:  https://onehealthdrugs.com/</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>